Iovance Biotherapeutics is trading at $9.17, up 5.38% in pre-market after its November 5 third-quarter results beat revenue estimates. - Third-quarter revenue reached $121.5 million, including approximately $102 million in Amtagvi sales. - The company reported a record 60% gross margin and a narrower $0.05-per-share loss, and reaffirmed full-year revenue guidance of $410 million–$420 million. - The release cited continued U.S. demand and more than 1,000 commercially treated Amtagvi patients.